MNK's hydrocodone and oxycodone sales were down 42% and 38%, respectively, from a year ago.
Here stays the opportunity for the smart one and the débâcle for the fool.
Generics are dead in terms of profitability. for the little IPCI they can still save the day but they better off sell them off and just concentrate (can they ?)on the NDA's and delivery tech.
Anything else is just short term survival